AbbVie wins Crohn's approval: what it means for AbbVie stock
Published on 10/26/2026 at 11:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline and earnings milestones
- The FDA approval for subcutaneous SKYRIZI induction in Crohn's disease was reported on October 26, 2026.
- Second-quarter revenue reached USD 16.99 billion, up 10.20 percent year over year.
- AbbVie stock trades at EUR 255.20 at 11:21 a.m. CEST at Lang & Schwarz on October 26, 2026, 0.31 percent above the Xetra close of October 23, 2026.
- BofA raised its target from USD 289.00 to USD 305.00 on October 9, 2026.
AbbVie Inc. (ISIN US00287Y1091) was trading at EUR 255.20 at Lang & Schwarz on October 26, 2026 at 11:21 a.m. CEST, 0.31 percent above the Xetra close of October 23, 2026 at EUR 254.40. MarketBeat reported on October 26, 2026 that the U.S. Food and Drug Administration approved a subcutaneous SKYRIZI induction regimen for adults with moderately to severely active Crohn's disease.
Approval adds a Crohn's route
The new regimen gives AbbVie another way to extend SKYRIZI in inflammatory bowel disease as the company manages Humira's loss of exclusivity. MarketBeat said the approval followed Phase 3 data showing higher clinical remission and endoscopic response than placebo, with no new safety risks reported.
What does the approval mean for growth?
AbbVie's second-quarter 2026 revenue reached USD 16.99 billion, up 10.20 percent from the year-earlier quarter, while adjusted earnings per share came to USD 3.65. Yahoo Finance reported that management raised full-year revenue guidance by USD 300 million during the July 31, 2026 earnings call and set third-quarter adjusted earnings per share guidance at USD 3.84 to USD 3.88.
The upcoming test is whether the newer portfolio can offset pressure on older products. Markets Insider reported on October 9, 2026 that BofA raised its AbbVie target from USD 289.00 to USD 305.00 while maintaining a Buy rating.
Three milestones since July
On July 31, 2026, AbbVie reported USD 16.99 billion in second-quarter revenue and adjusted earnings per share of USD 3.65. On October 9, 2026, BofA raised its target to USD 305.00 from USD 289.00. On October 26, 2026, MarketBeat reported the FDA approval for subcutaneous SKYRIZI induction in Crohn's disease.
Dates for earnings and payout
AbbVie scheduled its third-quarter 2026 results for October 30, 2026, before the U.S. market opens. MarketBeat also reported a USD 1.73 quarterly dividend payment for November 16, 2026.
Price holds above Xetra close
AbbVie had a USD 504.8 billion market capitalization, with a USD 190.75 to USD 291.40 52-week range as of October 23, 2026. The NYSE-listed stock was last quoted at USD 285.64 in the primary-market context on that date.
AbbVie stock was trading at EUR 255.20 at Lang & Schwarz on October 26, 2026 at 11:21 a.m. CEST, 0.31 percent above the Xetra close of October 23, 2026 at EUR 254.40. The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.
AbbVie stock facts
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: ABBV
- Primary exchange: NYSE
- Price Lang & Schwarz as of October 26, 2026, 11:21 a.m. CEST: EUR 255.20
- Change versus Xetra close: plus 0.31 percent
- Xetra close October 23, 2026: EUR 254.40
- Market capitalization: USD 504.8 billion (as of October 23, 2026)
- 52-week range: USD 190.75-291.40 (as of October 23, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Next earnings date: October 30, 2026
Market context: Market report S&P 500.
